Vermillion Inc (VRML) 2.08 $VRML
Vermillion passes ISO 13485 certification for Quality Management System
M2 - Fri Feb 13, 5:09AM CST
Bio-analytical solutions company Vermillion (Nasdaq:VRML) reported on Thursday the receipt of its ISO 13485:2003 quality management system from the British Standards Institution (BSI).
VRML: 2.08 (+0.12)
Vermillion Receives ISO 13485 Certification for Company's Quality Management System
PR Newswire - Thu Feb 12, 3:22PM CST
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that the Company has been awarded ISO 13485:2003 from the British Standards Institution (BSI), one of the world's leading certification bodies, for Vermillion's quality management system. ISO 13485:2003 certification is the internationally recognized quality standard for medical devices and diagnostics.
VRML: 2.08 (+0.12)
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
Meridian Bioscience: In-line Earnings, Revenue Beat in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 8:10AM CST
Diagnostic test-kit maker Meridian Bioscience, Inc. (VIVO) reported first-quarter fiscal 2015 (ended Dec 31, 2014) EPS of 19 cents, up 6% on a year-over-year basis and inline with the Zacks Consensus Estimate
VIVO: 19.15 (+0.16), AXDX: 22.86 (-0.33), IDXX: 159.08 (+1.72), VRML: 2.08 (+0.12)
Vermillion names Patrick Carpenter as GM of ASPiRA LABS
M2 - Wed Jan 14, 7:04AM CST
Bio-analytical solutions company Vermillion (Nasdaq:VRML) reported on Tuesday that Patrick Carpenter as been elected as general manager of its CLIA-certified national clinical laboratory, ASPiRA LABS.
VRML: 2.08 (+0.12)
Vermillion Appoints Patrick Carpenter as General Manager of ASPiRA LABS
PR Newswire - Tue Jan 13, 8:00AM CST
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that the Company has appointed Patrick Carpenter as General Manager of ASPiRA LABS, Vermillion's CLIA-certified national clinical laboratory. Mr. Carpenter will report directly to Valerie Palmieri, the Company's President & Chief Executive Officer.
DGX: 71.68 (+0.03), VRML: 2.08 (+0.12)
Vermillion Appoints Laura Miller as SVP of Sales/Customer Experience
PR Newswire - Mon Jan 12, 8:00AM CST
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that the Company has appointed Laura Miller to the newly created position of Senior Vice President of Sales/Customer Experience. Ms. Miller will report directly to Valerie Palmieri, President & Chief Executive Officer.
VRML: 2.08 (+0.12)
InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST
GD: 137.61 (-0.54), SKBI: 4.22 (+0.03), PTBI: 3.10 (unch), FMD: 5.45 (-0.16), GHC: 976.65 (+15.51), VRML: 2.08 (+0.12), ADBE: 76.51 (+1.92), OHAI: 4.67 (+0.01), KERX: 11.63 (-0.60), BH: 416.41 (-1.55), LII: 104.27 (+0.88), JAZZ: 169.69 (+6.89), NMBL: 23.19 (+0.81), REGN: 402.40 (+0.66), OAS: 16.84 (-0.03), XLRN: 38.02 (+0.07), SYK: 94.51 (+1.14), CRM: 62.85 (+1.59)
Vermillion Announces Closing of Equity Financing
PR Newswire - Wed Dec 24, 8:15AM CST
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that the Company closed its previously announced private placement with investors including Oracle Investment Management, Jack W. Schuler, Birchview Fund LLC and several Vermillion directors. Total proceeds were $10.5 million, before offering expenses. The proceeds will be used for working capital and general corporate purposes.
VRML: 2.08 (+0.12)
Midday Gainers /Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 11:45AM CST
NICK: 14.91 (unch), JRJC: 5.46 (+0.16), OCN: 9.10 (+0.09), ZAZA: 2.17 (+0.08), VNDA: 12.37 (unch), EPAX: 2.45 (+0.04), FES: 1.19 (+0.06), NQ: 3.95 (-0.03), TECU: 3.07 (-0.02), VRML: 2.08 (+0.12), MYOS: 5.45 (-0.20), PME: 2.42 (-0.07), ESPR: 67.13 (-0.33), ALNY: 95.54 (+1.67), IDSA: 5.82 (-0.08), PRLS: 6.96 (-0.02), ACHN: 10.89 (-0.20), SKYS: 10.55 (-0.65), RCPT: 115.83 (-0.66), AGIO: 118.55 (+0.11)
Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program
PR Newswire - Tue Dec 23, 8:15AM CST
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that investors including Oracle Investment Management, Jack W. Schuler, Birchview Fund LLC and several Vermillion directors have agreed to purchase approximately $10.5 million of unregistered shares of Vermillion's common stock and warrants to purchase unregistered shares of Vermillion common stock in a private placement.
VRML: 2.08 (+0.12)
Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board
PR Newswire - Tue Dec 16, 3:05PM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytic solutions company focused on gynecologic disease, today announced the next step in its expanded strategy to rebuild the company into a premier bio-analytics solutions provider with the naming of current Chief Operating Officer, Valerie Palmieri to President and Chief Executive Officer, while current Chairman of the Board and CEO James LaFrance will continue to serve as Chairman. These changes are effective January 1, 2015.
VRML: 2.08 (+0.12)
Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber
PR Newswire - Fri Dec 12, 8:00AM CST
Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today the appointments of Veronica G. H. Jordan, Ph.D., and David R. Schreiber to the Company's Board of Directors, bringing the total number of directors to eight, seven of whom are independent.
RGDX: 0.52 (+0.06), AMRI: 16.94 (-0.28), VRML: 2.08 (+0.12)
Vermillion Outlines Expanded Strategic Mission; Forms New Strategic & Medical Advisory Board
PR Newswire - Tue Nov 18, 4:45PM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, recently outlined its expanded strategy for driving improvements in the personalized management of gynecologic health and becoming the leading diagnostic innovator in gynecologic informatics. In support of this mission, the Company is naming three charter members of its Strategic & Medical Advisory Board.
VRML: 2.08 (+0.12)
Vermillion's (VRML) CEO James LaFrance on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 9:16PM CST
VRML: 2.08 (+0.12)
Vermillion (VRML) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 13, 3:25PM CST
VRML: 2.08 (+0.12)
Vermillion reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:06PM CST
VRML: 2.08 (+0.12)
Vermillion Reports Third Quarter 2014 Results and Announces Expanded Strategy
PR Newswire - Thu Nov 13, 3:01PM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its results for the quarter ended September 30, 2014.
VRML: 2.08 (+0.12)
Vermillion Sets Third Quarter 2014 Conference Call for Thursday, November 13, 2014
PR Newswire - Thu Oct 30, 3:01PM CDT
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on Thursday, November 13, 2014, at 4:30 p.m. Eastern time to discuss results for the third quarter ended September 30, 2014. Financial results will be issued in a press release prior to the call.
VRML: 2.08 (+0.12)
Vermillion passes ISO 13485 certification for Quality Management System
M2 - Fri Feb 13, 5:09AM CST
Bio-analytical solutions company Vermillion (Nasdaq:VRML) reported on Thursday the receipt of its ISO 13485:2003 quality management system from the British Standards Institution (BSI).
VRML: 2.08 (+0.12)
Vermillion Receives ISO 13485 Certification for Company's Quality Management System
PR Newswire - Thu Feb 12, 3:22PM CST
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that the Company has been awarded ISO 13485:2003 from the British Standards Institution (BSI), one of the world's leading certification bodies, for Vermillion's quality management system. ISO 13485:2003 certification is the internationally recognized quality standard for medical devices and diagnostics.
VRML: 2.08 (+0.12)
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
Meridian Bioscience: In-line Earnings, Revenue Beat in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 8:10AM CST
Diagnostic test-kit maker Meridian Bioscience, Inc. (VIVO) reported first-quarter fiscal 2015 (ended Dec 31, 2014) EPS of 19 cents, up 6% on a year-over-year basis and inline with the Zacks Consensus Estimate
VIVO: 19.15 (+0.16), AXDX: 22.86 (-0.33), IDXX: 159.08 (+1.72), VRML: 2.08 (+0.12)
Vermillion names Patrick Carpenter as GM of ASPiRA LABS
M2 - Wed Jan 14, 7:04AM CST
Bio-analytical solutions company Vermillion (Nasdaq:VRML) reported on Tuesday that Patrick Carpenter as been elected as general manager of its CLIA-certified national clinical laboratory, ASPiRA LABS.
VRML: 2.08 (+0.12)
Vermillion Appoints Patrick Carpenter as General Manager of ASPiRA LABS
PR Newswire - Tue Jan 13, 8:00AM CST
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that the Company has appointed Patrick Carpenter as General Manager of ASPiRA LABS, Vermillion's CLIA-certified national clinical laboratory. Mr. Carpenter will report directly to Valerie Palmieri, the Company's President & Chief Executive Officer.
DGX: 71.68 (+0.03), VRML: 2.08 (+0.12)
Vermillion Appoints Laura Miller as SVP of Sales/Customer Experience
PR Newswire - Mon Jan 12, 8:00AM CST
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that the Company has appointed Laura Miller to the newly created position of Senior Vice President of Sales/Customer Experience. Ms. Miller will report directly to Valerie Palmieri, President & Chief Executive Officer.
VRML: 2.08 (+0.12)
InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST
GD: 137.61 (-0.54), SKBI: 4.22 (+0.03), PTBI: 3.10 (unch), FMD: 5.45 (-0.16), GHC: 976.65 (+15.51), VRML: 2.08 (+0.12), ADBE: 76.51 (+1.92), OHAI: 4.67 (+0.01), KERX: 11.63 (-0.60), BH: 416.41 (-1.55), LII: 104.27 (+0.88), JAZZ: 169.69 (+6.89), NMBL: 23.19 (+0.81), REGN: 402.40 (+0.66), OAS: 16.84 (-0.03), XLRN: 38.02 (+0.07), SYK: 94.51 (+1.14), CRM: 62.85 (+1.59)
Vermillion Announces Closing of Equity Financing
PR Newswire - Wed Dec 24, 8:15AM CST
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that the Company closed its previously announced private placement with investors including Oracle Investment Management, Jack W. Schuler, Birchview Fund LLC and several Vermillion directors. Total proceeds were $10.5 million, before offering expenses. The proceeds will be used for working capital and general corporate purposes.
VRML: 2.08 (+0.12)
Midday Gainers /Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 11:45AM CST
NICK: 14.91 (unch), JRJC: 5.46 (+0.16), OCN: 9.10 (+0.09), ZAZA: 2.17 (+0.08), VNDA: 12.37 (unch), EPAX: 2.45 (+0.04), FES: 1.19 (+0.06), NQ: 3.95 (-0.03), TECU: 3.07 (-0.02), VRML: 2.08 (+0.12), MYOS: 5.45 (-0.20), PME: 2.42 (-0.07), ESPR: 67.13 (-0.33), ALNY: 95.54 (+1.67), IDSA: 5.82 (-0.08), PRLS: 6.96 (-0.02), ACHN: 10.89 (-0.20), SKYS: 10.55 (-0.65), RCPT: 115.83 (-0.66), AGIO: 118.55 (+0.11)
Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program
PR Newswire - Tue Dec 23, 8:15AM CST
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that investors including Oracle Investment Management, Jack W. Schuler, Birchview Fund LLC and several Vermillion directors have agreed to purchase approximately $10.5 million of unregistered shares of Vermillion's common stock and warrants to purchase unregistered shares of Vermillion common stock in a private placement.
VRML: 2.08 (+0.12)
Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board
PR Newswire - Tue Dec 16, 3:05PM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytic solutions company focused on gynecologic disease, today announced the next step in its expanded strategy to rebuild the company into a premier bio-analytics solutions provider with the naming of current Chief Operating Officer, Valerie Palmieri to President and Chief Executive Officer, while current Chairman of the Board and CEO James LaFrance will continue to serve as Chairman. These changes are effective January 1, 2015.
VRML: 2.08 (+0.12)
Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber
PR Newswire - Fri Dec 12, 8:00AM CST
Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today the appointments of Veronica G. H. Jordan, Ph.D., and David R. Schreiber to the Company's Board of Directors, bringing the total number of directors to eight, seven of whom are independent.
RGDX: 0.52 (+0.06), AMRI: 16.94 (-0.28), VRML: 2.08 (+0.12)
Vermillion Outlines Expanded Strategic Mission; Forms New Strategic & Medical Advisory Board
PR Newswire - Tue Nov 18, 4:45PM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, recently outlined its expanded strategy for driving improvements in the personalized management of gynecologic health and becoming the leading diagnostic innovator in gynecologic informatics. In support of this mission, the Company is naming three charter members of its Strategic & Medical Advisory Board.
VRML: 2.08 (+0.12)
Vermillion's (VRML) CEO James LaFrance on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 9:16PM CST
VRML: 2.08 (+0.12)
Vermillion (VRML) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 13, 3:25PM CST
VRML: 2.08 (+0.12)
Vermillion reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:06PM CST
VRML: 2.08 (+0.12)
Vermillion Reports Third Quarter 2014 Results and Announces Expanded Strategy
PR Newswire - Thu Nov 13, 3:01PM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its results for the quarter ended September 30, 2014.
VRML: 2.08 (+0.12)
Vermillion Sets Third Quarter 2014 Conference Call for Thursday, November 13, 2014
PR Newswire - Thu Oct 30, 3:01PM CDT
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on Thursday, November 13, 2014, at 4:30 p.m. Eastern time to discuss results for the third quarter ended September 30, 2014. Financial results will be issued in a press release prior to the call.
VRML: 2.08 (+0.12)
